Developments in Point-of-Care Diagnostic Technology for Cancer Detection

被引:69
作者
Hayes, Bryony [1 ]
Murphy, Caroline [2 ]
Crawley, Aoife [2 ]
O'Kennedy, Richard [2 ,3 ]
机构
[1] Univ Bristol Sch Med, Translat Hlth Sci, Dorothy Hodgkin Bldg,Whitson St, Bristol BS1 3NY, Avon, England
[2] Dublin City Univ, Sch Biotechnol, Collins Ave, Dublin D09 Y5N0, Ireland
[3] Hamad Bin Khalifa Univ, Res Complex,POB 34110, Doha, Qatar
来源
DIAGNOSTICS | 2018年 / 8卷 / 02期
基金
爱尔兰科学基金会;
关键词
cancer; diagnostics; point-of-care; glycosylation; circulating tumor cells; prostate cancer; biomarkers; exosomes; autoantibodies; PROSTATE-SPECIFIC ANTIGEN; CIRCULATING TUMOR-CELLS; ON-A-CHIP; COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; P53; AUTOANTIBODIES; SEMINAL PLASMA; PLANT-LECTINS; LUNG-CANCER; BIOMARKER;
D O I
10.3390/diagnostics8020039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths.
引用
收藏
页数:18
相关论文
共 107 条
[31]   Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis [J].
Filella, Xavier ;
Gimenez, Nuria .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (04) :729-739
[32]  
Fitzgerald Timothy L., 2014, Advances in Biological Regulation, V56, P45, DOI 10.1016/j.jbior.2014.05.001
[33]   The sweet and sour of cancer: Glycans as novel therapeutic targets [J].
Fuster, MM ;
Esko, JD .
NATURE REVIEWS CANCER, 2005, 5 (07) :526-542
[34]   Exosomes and their roles in immune regulation and cancer [J].
Greening, David W. ;
Gopal, Shashi K. ;
Xu, Rong ;
Simpson, Richard J. ;
Chen, Weisan .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2015, 40 :72-81
[35]   Mining the plasma proteome for cancer biomarkers [J].
Hanash, Samir M. ;
Pitteri, Sharon J. ;
Faca, Vitor M. .
NATURE, 2008, 452 (7187) :571-579
[36]   β1,6-Branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma [J].
Handerson, T ;
Camp, R ;
Harigopal, M ;
Rimm, D ;
Pawelek, J .
CLINICAL CANCER RESEARCH, 2005, 11 (08) :2969-2973
[37]   Clinically Meaningful Use of Blood Tumor Markers in Oncology [J].
Holdenrieder, Stefan ;
Pagliaro, Lance ;
Morgenstern, David ;
Dayyani, Farshid .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[38]   From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer [J].
Hori, Satoshi ;
Blanchet, Jean-Sebastien ;
McLoughlin, John .
BJU INTERNATIONAL, 2013, 112 (06) :717-728
[39]   Metabolomic profiling for early cancer detection: current status and future prospects [J].
Hwang, Vicki J. ;
Weiss, Robert H. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (11) :1263-1265
[40]  
Issadore David, 2015, Methods Mol Biol, V1256, P123, DOI 10.1007/978-1-4939-2172-0_9